Carnegie acted as joint bookrunner in the private placement of NOK 71 million in new equity by Oncoinvent.
Oncoinvent is an Oslo-based radiopharmaceutical company developing new treatments for cancer. The company’s lead drug candidate is currently in phase IIa clinical trials and is designed to safely deliver precise radiation dose to cancer cells in body cavities with minimal damage to healthy tissue.